Ga‐68‐PSMA‐11 in High‐Risk Prostate Cancer Trial: An open‐label, single‐arm, rater‐blinded, multicenter phase 1/2 study to assess safety and diagnostic accuracy and radiotherapeutic implications of pre‐operative Ga‐68‐PSMA‐11 PET/CT imaging in comparison to histopathology, in newly‐diagnosed prostate cancer (PCA) patients at high risk for metastasis, scheduled for radical prostatectomy (RP) with extended pelvic lymph node dissection (EPLND). The gene discussed is FOLH1; the disease is prostate carcinoma.